Top News: Kindred Biosciences (NASDAQ:KIN), Revance Therapeutics (NASDAQ:RVNC), Barclays PLC (ADR) (NYSE:BCS), Analogic Corporation (NASDAQ:ALOG), MeetMe (NASDAQ:MEET)


On Thursday shares of Kindred Biosciences, Inc. (NASDAQ:KIN) closed at $7.39. Company’s EPS growth for next 5 years is recorded as 15.00%. On May 08, Kindred Biosciences, Inc. (NASDAQ:KIN) reported first-quarter net loss of $6.7 million or $0.34 per share compared with a loss of $6.2 million or $0.38 per share.

Revance Therapeutics, Inc. (NASDAQ:RVNC) in last trading activity increased 19.71% to close at $24.29. Company weekly performance is 18.95% while its quarterly performance stands at 46.59%. Revance Therapeutics, Inc. (NASDAQ:RVNC) is -28.98% away from its 52 week high. Revance Therapeutics, Inc. (NASDAQ:RVNC), announced financial results for the first quarter ended March 31, 2015. Net loss for the quarter ended March 31, 2015 was $15.4 million compared to $21.4 million for the same period in 2014. Interest expense for the quarter ended March 31, 2015 was $0.2 million.

On last trading day Barclays PLC (ADR) (NYSE:BCS) increased 0.91% to close at $16.56. Its volatility for the week is 1.05% while volatility for the month is 1.22%. BCS’s sales growth for past 5 years was -3.90% and its EPS growth for past 5 years was -15.40%. Barclays PLC (ADR) (NYSE:BCS) monthly performance is 7.07%. Barclays PLC (ADR) (NYSE:BCS) will probably be fined for violating a three-year-old settlement over interest-rate rigging, but U.S. prosecutors will stop short of seeking a guilty plea, which they are demanding from UBS AG, people familiar with the matter said.

Analogic Corporation (NASDAQ:ALOG) has 0.50% insider ownership while its institutional ownership stands at 98.60%. In last trading activity company’s stock closed at $87.17. Zacks upgraded shares of Analogic (NASDAQ:ALOG) from a hold rating to a buy rating in a research note issued to investors on Wednesday. The firm currently has $95.00 price target on the stock.

On last trading day MeetMe, Inc. (NASDAQ:MEET) increased 2.40% to close at $1.71. Its volatility for the week is 5.23% while volatility for the month is 4.37%. MEET’s sales growth for past 5 years was 145.70% and its EPS growth for past 5 years was 34.70%. MeetMe Inc. (NASDAQ:MEET) on May 07, reported first-quarter net income of $722,000, after reporting a loss in the same period a year earlier.


Leave a Reply

Your email address will not be published. Required fields are marked *